AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone, aimed at promoting lipolysis without the growth-promoting effects. Its primary application focuses on metabolic disorders and weight management, showing promise in enhancing fat oxidation and recovery in orthopedic and sports medicine. Despite favorable safety profiles, AOD-9604 remains unapproved for therapeutic use in major jurisdictions, necessitating further clinical trials to establish its efficacy.
subcutaneous, intramuscular
0.25-1.0 mg daily
2-4 hours
Refrigerated storage required
growth_hormone_receptors, adipocyte_receptors
AOD-9604 represents a synthetic peptide fragment derived from the C-terminal region of human growth hormone, specifically encompassing amino acids 176-191 . This 16-amino acid sequence was identified and developed as part of research efforts to isolate the lipolytic properties of growth hormone while eliminating its growth-promoting and diabetogenic effects .
growth_hormone_receptors
adipocyte_receptors
Research Use Only (RUO) - AOD-9604 Research Monograph: Overview and Applications is currently available for research purposes only and is not approved by regulatory agencies for human therapeutic use.
This report is generated for educational and informational purposes only. All research content is compiled from credible, peer-reviewed, and verified external scientific sources. This material does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional before making any decisions related to your health or treatment.
Tesamorelin is a synthetic peptide used primarily for reducing abdominal fat in HIV patients. This article explores its mechanism of action, detailing how it influences growth hormone release and impacts fat metabolism.
April 21, 2026
Explore the comprehensive guide to Tesamorelin, a peptide used for reducing visceral fat in HIV patients. Learn about its mechanisms, benefits, and recommended dosages. Discover recent research and its potential future applications.
April 18, 2026